 Praxis Precision Medicines Incs NASDAQ: PRAX Phase 23 Aria Study of PRAX-114 for major depressive disorder MDD did not achieve statistical significance on the primary endpoint. The primary endpoint was the change from baseline in the total score of the 17-item Hamilton. 